NAMSW vs NCNA

NewAmsterdam Pharma Company N.V vs NuCana plc — Valuation Comparison 2026

NAMSW

Pharmaceutical Preparations
NewAmsterdam Pharma Company N.V
Quality
2.2
out of 10
Value Trap
Price
$25.00
Last close
Models
8/13
Active
VS

NCNA

Pharmaceutical Preparations
NuCana plc
Quality
1.7
out of 10
Value Trap
Price
$2.33
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType NAMSW Fair ValueNAMSW Upside NCNA Fair ValueNCNA Upside
Bayesian DCF Intrinsic $0.54 -76.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.60 -83.1% $11.95 +412.8%
Dynamic NAV Asset-Based $6.79 -68.0% $3.98 +71.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAMSW vs NCNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAMSW vs NCNA — Which Stock Is More Undervalued?

NAMSW scores higher with a 2.2/10 quality rating vs NCNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NewAmsterdam Pharma Company N.V (NAMSW) and NuCana plc (NCNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAMSW currently trades at $25.00 with a QOC of 2.2/10, while NCNA trades at $2.33 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).